{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:34:43Z","timestamp":1794980083575,"version":"4.9.1"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.atherosclerosis.2024.119053","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T08:16:35Z","timestamp":1731572195000},"page":"119053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"special_numbering":"C","title":["Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)"],"prefix":"10.1016","volume":"400","author":[{"given":"Santiago","family":"Iturbe-Rey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Maccali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Arrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Aspichueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia P.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui E.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa","family":"Lapitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Izquierdo-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Bujanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Perugorria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus M.","family":"Banales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6193-7436","authenticated-orcid":false,"given":"Pedro M.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2024.119053_bib1","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach","volume":"28","author":"Le","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jhep.2023.01.026","article-title":"Healthcare and socioeconomic costs of NAFLD: a global framework to navigate the uncertainties","volume":"79","author":"Allen","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000352","article-title":"The changing epidemiology of adult liver transplantation in the United States in 2013-2022: the dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease","volume":"8","author":"Younossi","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib6","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib8","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib9","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/MEG.0000000000001684","article-title":"Nonalcoholic fatty liver disease is associated with intrahepatic cholangiocarcinoma and not with extrahepatic form: definitive evidence from meta-analysis and trial sequential analysis","volume":"33","author":"Corrao","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/biom12060824","article-title":"NAFLD: mechanisms, treatments, and biomarkers","volume":"12","author":"Nassir","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib12","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","article-title":"Recent insights into the pathogenesis of nonalcoholic fatty liver disease","volume":"13","author":"Arab","year":"2018","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib14","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18105227","article-title":"Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors","volume":"18","author":"Juanola","year":"2021","journal-title":"Int. J. Environ. Res. Publ. Health"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib16","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jhep.2023.01.024","article-title":"An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease","volume":"78","author":"Lee","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib17","doi-asserted-by":"crossref","first-page":"G469","DOI":"10.1152\/ajpgi.00049.2020","article-title":"An overview of deregulated lipid metabolism in nonalcoholic fatty liver disease with special focus on lysosomal acid lipase","volume":"319","author":"Carotti","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib18","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib19","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib20","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib21","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1194\/jlr.R066514","article-title":"Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment","volume":"57","author":"Ertunc","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.gastro.2018.06.031","article-title":"Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis","volume":"155","author":"Musso","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib23","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1111\/liv.15059","article-title":"The role of hepatic lipid composition in obesity-related metabolic disease","volume":"41","author":"Willis","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1055\/s-0028-1091981","article-title":"Mechanisms of disease progression in nonalcoholic fatty liver disease","volume":"28","author":"Jou","year":"2008","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib25","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/MOL.0b013e3282ff5e55","article-title":"Hepatic triglyceride synthesis and nonalcoholic fatty liver disease","volume":"19","author":"Choi","year":"2008","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib26","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.tips.2017.04.004","article-title":"Roles of diacylglycerols and ceramides in hepatic insulin resistance","volume":"38","author":"Petersen","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166149","article-title":"TRIM56 protects against nonalcoholic fatty liver disease by promoting the degradation of fatty acid synthase","volume":"134","author":"Xu","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib28","first-page":"1","article-title":"Triglyceride metabolism in the liver","volume":"8","author":"Alves-Bezerra","year":"2017","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib29","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/13543784.2020.1668374","article-title":"GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)","volume":"29","author":"Alkhouri","year":"2020","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The role of cholesterol in the pathogenesis of NASH","volume":"27","author":"Ioannou","year":"2016","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib32","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.bbadis.2015.05.015","article-title":"Recent insights on the role of cholesterol in non-alcoholic fatty liver disease","volume":"1852","author":"Arguello","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib33","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cmet.2012.04.004","article-title":"Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease","volume":"15","author":"Min","year":"2012","journal-title":"Cell Metabol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hep4.1801","article-title":"Role of cholesterol-associated steatohepatitis in the development of NASH","volume":"6","author":"Horn","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100638","article-title":"Emerging therapies for MASLD and their impact on plasma lipids","volume":"17","author":"Nguyen","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00535-010-0291-8","article-title":"Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease","volume":"46","author":"Park","year":"2011","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib37","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.cmet.2008.04.001","article-title":"The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1","volume":"7","author":"Ge","year":"2008","journal-title":"Cell Metabol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib38","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?","volume":"11","author":"Rada","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117237","article-title":"Hepatic fatty acid and glucose handling in metabolic disease: potential impact on cardiovascular disease risk","volume":"394","author":"Westcott","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113869","article-title":"Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis","volume":"176","author":"Kumar","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib41","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/hep.29689","article-title":"New insights into the role and mechanism of c-Jun-N-terminal kinase signaling in the pathobiology of liver diseases","volume":"67","author":"Win","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib42","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/hep.27175","article-title":"Saturated free fatty acids induce cholangiocyte lipoapoptosis","volume":"60","author":"Natarajan","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib43","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2010.01.003","article-title":"Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis","volume":"52","author":"Akazawa","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.plefa.2009.05.020","article-title":"The essentiality of arachidonic acid and docosahexaenoic acid","volume":"81","author":"Le","year":"2009","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib45","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-nutr-071812-161230","article-title":"Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease","volume":"33","author":"Scorletti","year":"2013","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib46","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.nutres.2013.07.004","article-title":"A high ratio of dietary n-3\/n-6 polyunsaturated fatty acids improves obesity-linked inflammation and insulin resistance through suppressing activation of TLR4 in SD rats","volume":"33","author":"Liu","year":"2013","journal-title":"Nutr. Res."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib47","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2409262121","article-title":"Phosphorylation of Insig-2 mediates inhibition of fatty acid synthesis by polyunsaturated fatty acids","volume":"121","author":"Tian","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib48","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1080\/10408398.2018.1544542","article-title":"n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: a critical review","volume":"59","author":"Wang","year":"2019","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/srep31587","article-title":"Hepatic and serum lipid signatures specific to nonalcoholic steatohepatitis in murine models","volume":"6","author":"Chiappini","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib50","doi-asserted-by":"crossref","first-page":"G77","DOI":"10.1152\/ajpgi.00301.2011","article-title":"Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis","volume":"302","author":"Kakisaka","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plipres.2008.08.001","article-title":"Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)","volume":"48","author":"Musso","year":"2009","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib52","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1194\/jlr.R066357","article-title":"Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis","volume":"57","author":"Hirsova","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib53","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/jhbp.256","article-title":"Cholangiocyte senescence caused by lysophosphatidylcholine as a potential implication in carcinogenesis","volume":"22","author":"Shimizu","year":"2015","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib54","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/hep.28973","article-title":"Hepatocyte autotaxin expression promotes liver fibrosis and cancer","volume":"65","author":"Kaffe","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4419-6741-1_1","article-title":"An overview of sphingolipid metabolism: from synthesis to breakdown","volume":"688","author":"Gault","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib56","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1478-3231.2007.01475.x","article-title":"Sphingolipid signalling and liver diseases","volume":"27","author":"Mar\u00ed","year":"2007","journal-title":"Liver Int."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115157","article-title":"Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives","volume":"202","author":"Yu","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib58","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41569-021-00536-1","article-title":"Ceramides and other sphingolipids as drivers of cardiovascular disease","volume":"18","author":"Choi","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib59","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nature17041","article-title":"Protein misfolding in the endoplasmic reticulum as a conduit to human disease","volume":"529","author":"Wang","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib60","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/hep.32562","article-title":"Endoplasmic reticulum stress in liver diseases","volume":"77","author":"Ajoolabady","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib61","article-title":"Mammalian integrated stress responses in stressed organelles and their functions","author":"Lu","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib62","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.devcel.2008.10.015","article-title":"UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators","volume":"15","author":"Rutkowski","year":"2008","journal-title":"Dev. Cell"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib63","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.cmet.2008.04.011","article-title":"Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice","volume":"7","author":"Oyadomari","year":"2008","journal-title":"Cell Metabol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib64","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/s41419-020-03264-5","article-title":"Phosphorylation of eIF2\u03b1 signaling pathway attenuates obesity-induced non-alcoholic fatty liver disease in an ER stress and autophagy-dependent manner","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib65","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cmet.2011.11.004","article-title":"Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease","volume":"14","author":"Sunny","year":"2011","journal-title":"Cell Metabol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib66","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jhep.2011.05.019","article-title":"Lipotoxicity in NASH","volume":"56","author":"Fuchs","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib67","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s00018-016-2161-x","article-title":"Pathogenesis of nonalcoholic steatohepatitis","volume":"73","author":"Liu","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib68","doi-asserted-by":"crossref","first-page":"33425","DOI":"10.1074\/jbc.M109.049478","article-title":"Effect of anaplerotic fluxes and amino acid availability on hepatic lipoapoptosis","volume":"284","author":"Noguchi","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib69","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.nut.2008.07.023","article-title":"Nutritional lipid-induced oxidative stress leads to mitochondrial dysfunction followed by necrotic death in FaO hepatocytes","volume":"25","author":"Tirosh","year":"2009","journal-title":"Nutrition"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib70","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchemneu.2017.11.009","article-title":"Mitochondrial SIRT3 and neurodegenerative brain disorders","volume":"95","author":"Anamika","year":"2019","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib71","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41418-019-0356-z","article-title":"SIRT3 promotes lipophagy and chaperon-mediated autophagy to protect hepatocytes against lipotoxicity","volume":"27","author":"Zhang","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib72","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.redox.2018.07.011","article-title":"Therapeutic effect of Sirtuin 3 on ameliorating nonalcoholic fatty liver disease: the role of the ERK-CREB pathway and Bnip3-mediated mitophagy","volume":"18","author":"Li","year":"2018","journal-title":"Redox Biol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib73","doi-asserted-by":"crossref","first-page":"14608","DOI":"10.1073\/pnas.1111308108","article-title":"Sirtuin-3 (Sirt3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production","volume":"108","author":"Jing","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib74","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.2337\/db14-1810","article-title":"SIRT3 is crucial for maintaining skeletal muscle insulin action and protects against severe insulin resistance in high-fat-fed mice","volume":"64","author":"Lantier","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111299","article-title":"Paricalcitol attenuates oxidative stress and inflammatory response in the liver of NAFLD rats by regulating FOXO3a and NF\u03baB acetylation","volume":"121","author":"Malladi","year":"2024","journal-title":"Cell. Signal."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib76","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1113\/JP280908","article-title":"Nad","volume":"600","author":"Dall","year":"2022","journal-title":"J. Physiol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib77","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7570\/jomes23054","article-title":"Mitochondrial quality control: its role in metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"32","author":"Shin","year":"2023","journal-title":"J Obes Metab Syndr"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib78","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/med.21574","article-title":"JNK signaling in cancer cell survival","volume":"39","author":"Wu","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib79","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1007\/s00125-011-2130-8","article-title":"Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease","volume":"54","author":"Ferreira","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib80","doi-asserted-by":"crossref","first-page":"26591","DOI":"10.1074\/jbc.M109.022491","article-title":"JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis","volume":"284","author":"Cazanave","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib81","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1053\/j.gastro.2007.10.039","article-title":"Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease","volume":"134","author":"Puri","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib82","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.22578","article-title":"Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance","volume":"49","author":"Singh","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109587","article-title":"A small-molecule JNK inhibitor JM-2 attenuates high-fat diet-induced non-alcoholic fatty liver disease in mice","volume":"115","author":"Jin","year":"2023","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156671","article-title":"Ebselen improves lipid metabolism by activating PI3K\/Akt and inhibiting TLR4\/JNK signaling pathway to alleviate nonalcoholic fatty liver","volume":"181","author":"Pan","year":"2024","journal-title":"Cytokine"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib85","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2024.01.029","article-title":"Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice","volume":"80","author":"Zou","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib86","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib87","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cell.2023.11.044","article-title":"Cell death","volume":"187","author":"Newton","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib88","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s41423-020-00630-3","article-title":"Necroptosis, pyroptosis and apoptosis: an intricate game of cell death","volume":"18","author":"Bertheloot","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib89","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cbin.11137","article-title":"Cell death: a review of the major forms of apoptosis, necrosis and autophagy","volume":"43","author":"D'Arcy","year":"2019","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib90","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/bjc.1972.33","article-title":"Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics","volume":"26","author":"Kerr","year":"1972","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib91","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1194\/jlr.M071357","article-title":"FoxO3 increases miR-34a to cause palmitate-induced cholangiocyte lipoapoptosis","volume":"58","author":"Natarajan","year":"2017","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib92","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/gut.2006.118059","article-title":"Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity","volume":"56","author":"Malhi","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib93","doi-asserted-by":"crossref","first-page":"12093","DOI":"10.1074\/jbc.M510660200","article-title":"Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis","volume":"281","author":"Malhi","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib94","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hep.20283","article-title":"Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway","volume":"40","author":"Feldstein","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib95","doi-asserted-by":"crossref","first-page":"39336","DOI":"10.1074\/jbc.M111.280420","article-title":"Death receptor 5 signaling promotes hepatocyte lipoapoptosis","volume":"286","author":"Cazanave","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib96","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jhep.2014.11.033","article-title":"TRAIL receptor deletion in mice suppresses the inflammation of nutrient excess","volume":"62","author":"Idrissova","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib97","doi-asserted-by":"crossref","first-page":"14463","DOI":"10.1074\/jbc.M112.437210","article-title":"Metabolomic profiling reveals a role for caspase-2 in lipoapoptosis","volume":"288","author":"Johnson","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib98","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.19","article-title":"Caspase-2 promotes obesity, the metabolic syndrome and nonalcoholic fatty liver disease","volume":"7","author":"Machado","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib99","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1042\/CS20190068","article-title":"Processes exacerbating apoptosis in non-alcoholic steatohepatitis","volume":"133","author":"Afonso","year":"2019","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib100","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/82732","article-title":"Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule","volume":"1","author":"Holler","year":"2000","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib101","doi-asserted-by":"crossref","first-page":"20054","DOI":"10.1073\/pnas.1116302108","article-title":"Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway","volume":"108","author":"He","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib102","doi-asserted-by":"crossref","first-page":"31268","DOI":"10.1074\/jbc.M113.462341","article-title":"Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL","volume":"288","author":"Kaiser","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib103","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.44452","article-title":"Autophagy regulates inflammatory programmed cell death via turnover of RHIM-domain proteins","volume":"8","author":"Lim","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib104","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/cdd.2016.153","article-title":"Induction of necroptotic cell death by viral activation of the RIG-I or STING pathway","volume":"24","author":"Schock","year":"2017","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib105","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.4049\/jimmunol.1701492","article-title":"Intracellular nucleic acid sensing triggers necroptosis through synergistic type I IFN and TNF signaling","volume":"200","author":"Brault","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib106","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1073\/pnas.1717190115","article-title":"PUMA amplifies necroptosis signaling by activating cytosolic DNA sensors","volume":"115","author":"Chen","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib107","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.molcel.2011.06.006","article-title":"The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs","volume":"43","author":"Tenev","year":"2011","journal-title":"Mol. Cell."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib108","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.molcel.2011.06.011","article-title":"cIAPs block Ripoptosome formation, a RIP1\/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms","volume":"43","author":"Feoktistova","year":"2011","journal-title":"Mol. Cell."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib109","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.immuni.2013.06.018","article-title":"The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism","volume":"39","author":"Murphy","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib110","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1042\/CS20140732","article-title":"Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis","volume":"129","author":"Afonso","year":"2015","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib111","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.15252\/emmm.201403856","article-title":"A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis","volume":"6","author":"Gautheron","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib112","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1136\/gutjnl-2020-321767","article-title":"RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease","volume":"70","author":"Afonso","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib113","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.chembiol.2017.08.026","article-title":"Very long chain fatty acids are functionally involved in necroptosis","volume":"24","author":"Parisi","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib114","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1074\/jbc.RA118.005865","article-title":"Receptor-interacting Ser\/Thr kinase 1 (RIPK1) and myosin IIA-dependent ceramidosomes form membrane pores that mediate blebbing and necroptosis","volume":"294","author":"Nganga","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104439","article-title":"Necroptosis signaling in liver diseases: an update","volume":"148","author":"Saeed","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib116","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41420-020-0240-0","article-title":"Phenotypic high-throughput screening platform identifies novel chemotypes for necroptosis inhibition","volume":"6","author":"Brito","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib117","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nchembio711","article-title":"Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury","volume":"1","author":"Degterev","year":"2005","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib118","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nchembio.83","article-title":"Identification of RIP1 kinase as a specific cellular target of necrostatins","volume":"4","author":"Degterev","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib119","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.molmet.2019.02.003","article-title":"The pseudokinase MLKL regulates hepatic insulin sensitivity independently of inflammation","volume":"23","author":"Xu","year":"2019","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib120","article-title":"Inhibition of Receptor-Interacting Protein Kinase 1 with Necrostatin-1s ameliorates disease progression in elastase-induced mouse abdominal aortic aneurysm model","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib121","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.freeradbiomed.2020.12.449","article-title":"Role of necroptosis in chronic hepatic inflammation and fibrosis in a mouse model of increased oxidative stress","volume":"164","author":"Mohammed","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib122","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature10510","article-title":"The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus","volume":"477","author":"Zhao","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib123","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/ni.1864","article-title":"The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses","volume":"11","author":"Rathinam","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib124","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature13449","article-title":"Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome","volume":"513","author":"Xu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib125","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1055\/s-0037-1601350","article-title":"Inflammasomes in liver fibrosis","volume":"37","author":"Alegre","year":"2017","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib126","article-title":"The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD)","volume":"12","author":"Li","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib127","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/hep.26592","article-title":"NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice","volume":"59","author":"Wree","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib128","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00109-014-1170-1","article-title":"NLRP3 inflammasome activation is required for fibrosis development in NAFLD","volume":"92","author":"Wree","year":"2014","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib129","article-title":"Loss of PPAR\u03b1 function promotes epigenetic dysregulation of lipid homeostasis driving ferroptosis and pyroptosis lipotoxicity in metabolic dysfunction associated Steatotic liver disease (MASLD)","volume":"3","author":"Theys","year":"2023","journal-title":"Front Mol Med"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105088","article-title":"Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease: revisiting hepatic lipid peroxidation","volume":"102","author":"Peleman","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib131","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00109-019-01796-8","article-title":"Skeletal muscle miR-34a\/SIRT1:AMPK axis is activated in experimental and human non-alcoholic steatohepatitis","volume":"97","author":"Sim\u00e3o","year":"2019","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib132","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jhep.2012.08.008","article-title":"miR-34a\/SIRT1\/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease","volume":"58","author":"Castro","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib133","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1016-8478(23)12877-9","article-title":"The modulation of inflammatory gene expression by lipids: mediation through Toll-like receptors","volume":"21","author":"Lee","year":"2006","journal-title":"Mol. Cell."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib134","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1161\/01.ATV.0000183883.72263.13","article-title":"A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha","volume":"25","author":"Suganami","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib135","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010024","article-title":"Metabolic hallmarks of hepatic stellate cells in liver fibrosis","volume":"9","author":"Khomich","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib136","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MOL.0000000000000535","article-title":"Non-parenchymal hepatic cell lipotoxicity and the coordinated progression of non-alcoholic fatty liver disease and atherosclerosis","volume":"29","author":"Peters","year":"2018","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib137","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.trsl.2016.08.006","article-title":"Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress","volume":"180","author":"Li","year":"2017","journal-title":"Transl. Res."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib138","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12967-018-1490-y","article-title":"CCL20 is up-regulated in non-alcoholic fatty liver disease fibrosis and is produced by hepatic stellate cells in response to fatty acid loading","volume":"16","author":"Chu","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib139","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-020-00411-3","article-title":"Role of liver sinusoidal endothelial cells in liver diseases","volume":"18","author":"Gracia-Sancho","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib140","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143690","article-title":"Lipid-induced endothelial vascular cell adhesion molecule 1 promotes nonalcoholic steatohepatitis pathogenesis","volume":"131","author":"Furuta","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib141","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.freeradbiomed.2017.12.019","article-title":"The NOX1 isoform of NADPH oxidase is involved in dysfunction of liver sinusoids in nonalcoholic fatty liver disease","volume":"115","author":"Matsumoto","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib142","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib143","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.3748\/wjg.v19.i41.6969","article-title":"PNPLA3 I148M polymorphism and progressive liver disease","volume":"19","author":"Dongiovanni","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib144","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib145","doi-asserted-by":"crossref","first-page":"C880","DOI":"10.1152\/ajpcell.00413.2023","article-title":"BI-3231, an enzymatic inhibitor of HSD17B13, reduces lipotoxic effects induced by palmitic acid in murine and human hepatocytes","volume":"326","author":"Alcober-Boquet","year":"2024","journal-title":"Am. J. Physiol.: Cell Physiol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib146","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jhep.2023.05.007","article-title":"Therapeutic opportunities for the treatment of NASH with genetically validated targets","volume":"79","author":"Lind\u00e9n","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib147","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1056\/NEJMc2402341","article-title":"Phase 1 trials of PNPLA3 siRNA in I148M homozygous patients with MAFLD","volume":"391","author":"Fabbrini","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib148","first-page":"533","article-title":"Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease","volume":"73","author":"Lee","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib149","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1244405","article-title":"Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease","volume":"14","author":"Semmler","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib150","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/0008-5472.CAN-20-2052","article-title":"E2F1 and E2F2-mediated repression of CPT2 establishes a lipid-rich tumor-promoting environment","volume":"81","author":"Gonz\u00e1lez-Romero","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib151","article-title":"miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice","volume":"8","author":"Rodrigues","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib152","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/liv.15682","article-title":"miR-21-5p promotes NASH-related hepatocarcinogenesis","volume":"43","author":"Rodrigues","year":"2023","journal-title":"Liver Int."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib153","article-title":"Molecular mechanisms in MASLD\/MASH related HCC","author":"Wang","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib154","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41419-020-2283-9","article-title":"Hepatocyte apoptosis is tumor promoting in murine nonalcoholic steatohepatitis","volume":"11","author":"Hirsova","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib155","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/hep.32756","article-title":"RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabolic liver disease","volume":"77","author":"Afonso","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib156","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/cas.14828","article-title":"NAFLD exacerbates cholangitis and promotes cholangiocellular carcinoma in mice","volume":"112","author":"Maeda","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib157","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib158","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib159","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib160","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib161","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib162","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib163","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jhep.2014.08.036","article-title":"Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial","volume":"62","author":"Argo","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib164","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib165","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib166","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib167","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(24)00246-2","article-title":"Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial","author":"Loomba","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib169","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: current perspectives of resmetirom","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib170","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1210\/me.2008-0311","article-title":"Distinct dysregulation of lipid metabolism by unliganded thyroid hormone receptor isoforms","volume":"23","author":"Araki","year":"2009","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib171","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1007\/s00125-012-2592-3","article-title":"Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes","volume":"55","author":"Lee","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib172","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.atherosclerosis.2024.119053_bib173","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1136\/gutjnl-2024-333074","article-title":"Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease","volume":"73","author":"Zhou","year":"2024","journal-title":"Gut"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024012255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024012255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T17:19:11Z","timestamp":1733764751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915024012255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":173,"alternative-id":["S0021915024012255"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.119053","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.119053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"119053"}}